Participants with obesity (a body-mass index [BMI] of 30) and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain were randomly assigned 2:1 to receive once-weekly subcutaneous semaglutide (2.4 mg) or placebo, in addition to counseling on physical activity and a reduced-calorie diet
Until then, the evidence remains promising but preliminary
Record the restart date in the patients chart for ongoing care coordination Record the precise restart date, dose, route, and any rationale or precautions in the EHR
With our experienced providers, you can begin your weight loss journey with confidence in a safe and supportive environment
Licensed nurses are available throughout the treatment period for dosage questions, side effect management, and ongoing care guidance
Many labs use Bacteriostatic Water 10 ml